Novelion Therapeutics Inc. provided the earnings guidance for the year 2019. For the period, the company expects total net revenues in 2019 to be between $160.0 million and $175.0 million, including approximately $30.0 million of licensing revenues, in the form of the $25.0 million upfront licensing payment and $5.0 million payment upon transfer of the marketing authorization to Recordati Rare Diseases Inc., resulting from the licensing agreement entered into between Aegerion and Recordati for the commercialization of JUXTAPID in Japan in February 2019.